ValuEngine upgraded shares of Cerecor (NASDAQ:CERC) from a hold rating to a buy rating in a report issued on Wednesday, ValuEngine reports.

Other equities research analysts have also recently issued research reports about the stock. Maxim Group reissued a buy rating and issued a $10.00 price target on shares of Cerecor in a research note on Friday, November 15th. HC Wainwright reissued a buy rating and issued a $12.00 price target (up previously from $11.00) on shares of Cerecor in a research note on Monday, December 2nd. Oppenheimer started coverage on shares of Cerecor in a research note on Friday, January 10th. They issued an outperform rating and a $11.00 price target on the stock. Finally, LADENBURG THALM/SH SH reissued a buy rating and issued a $10.00 price target on shares of Cerecor in a research note on Friday, December 6th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $10.75.

Cerecor stock traded up $0.13 during trading on Wednesday, reaching $5.02. The company had a trading volume of 4,836 shares, compared to its average volume of 143,289. The firm’s 50-day simple moving average is $4.50 and its 200 day simple moving average is $3.88. Cerecor has a 1-year low of $2.91 and a 1-year high of $7.65. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.73 and a quick ratio of 0.71.

Cerecor (NASDAQ:CERC) last released its quarterly earnings results on Thursday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. Cerecor had a negative net margin of 113.66% and a negative return on equity of 121.32%. The firm had revenue of $5.61 million for the quarter, compared to analysts’ expectations of $5.15 million. As a group, equities research analysts anticipate that Cerecor will post -0.37 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp raised its holdings in shares of Cerecor by 47.4% during the 2nd quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock worth $304,000 after acquiring an additional 17,999 shares during the period. Bank of New York Mellon Corp raised its holdings in Cerecor by 294.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock valued at $312,000 after buying an additional 42,885 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in Cerecor in the 2nd quarter valued at about $288,000. State Street Corp raised its holdings in Cerecor by 20.6% in the 3rd quarter. State Street Corp now owns 342,223 shares of the company’s stock valued at $1,126,000 after buying an additional 58,538 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Cerecor by 612.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,670 shares of the company’s stock valued at $355,000 after buying an additional 62,473 shares during the period. Institutional investors and hedge funds own 60.84% of the company’s stock.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Read More: What are municipal bonds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.